Comparative Pharmacology
Head-to-head clinical analysis: METRO I V versus METROLOTION.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METRO I V versus METROLOTION.
METRO I.V. vs METROLOTION
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metronidazole is a nitroimidazole antibiotic that exerts its bactericidal effect by entering bacterial cells and undergoing reduction by bacterial nitroreductases to form reactive intermediates that damage DNA, leading to cell death. It is selectively toxic to anaerobic bacteria and protozoa.
Metrolotion is a formulation of metronidazole, a nitroimidazole antibiotic. Its exact mechanism is not fully understood, but it is believed to involve reduction of the nitro group in anaerobic bacteria and protozoa, leading to DNA disruption and cell death. It also has anti-inflammatory and immunosuppressive properties, possibly by inhibiting neutrophil chemotaxis and reactive oxygen species.
15-30 mg/kg IV loading dose, then 7.5-15 mg/kg IV every 6 hours. Typical adult dose: 500 mg IV every 6-8 hours.
Topical metronidazole (Metrolotion) 1%: Apply a thin layer to affected areas once daily.
None Documented
None Documented
8 hours (range 6-10 hours) in adults; prolonged to 12-24 hours in hepatic impairment.
Terminal elimination half-life is 18-24 hours; allows once-daily dosing.
Renal: 60-80% unchanged; fecal: 6-15% (includes metabolites); biliary: minor contribution.
Renal: 70% as unchanged drug; biliary/fecal: 30% as metabolites.
Category C
Category C
Antibiotic (Nitroimidazole)
Antibiotic (Nitroimidazole)